Inhibrx Biosciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INBX research report →
Range $245 – $245
Price Chart
About the company
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function.
- CEO
- Mark Lappe
- IPO
- 2024
- Employees
- 110
- HQ
- La Jolla, CA, US
Get TickerSpark's AI analysis on INBX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.02B
- P/E
- -7.62
- Fwd P/E
- 17.66
- PEG
- -0.73
- P/S
- 508.20
- P/B
- -12.64
- EV/EBITDA
- -9.14
- Div Yield
- 0.00%
- Gross Margin
- 19.25%
- Op Margin
- -6286.70%
- Net Margin
- -7082.90%
- ROE
- 373.04%
- ROIC
- -64.29%
Latest fiscal year · YoY change
- Revenue
- $1.30M+550.0%
- Gross Profit
- $-1,183,000+43.3%
- Op Income
- $-135,025,000
- Net Income
- $-140,055,000-108.3%
- EPS
- $-9.04-107.8%
- OCF Growth
- +33.2%
- FCF Growth
- +34.1%
- 52W High
- $155.29
- 52W Low
- $57.30
- 50D MA
- $91.98
- 200D MA
- $92.54
- Beta
- 4.04
- RSI (14)
- 37
- Avg Volume
- 305.47K
No earnings-call transcripts are available for INBX yet.
- Free Float
- 74.7%
- Shares Outstanding
- 14.72M
- Float Shares
- 11.00M
of shares held by institutions
178 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Morgan Stanley | 1.32M | ▲ 12.61K |
| Perceptive Advisors LLC | 1.29M | ▼ 5.30K |
| Sanofi | 1.16M | 0 |
| Viking Global Investors LP | 1.11M | ▼ 15.92K |
| Hightower Advisors, LLC | 884.44K | ▲ 13.89K |
| Schonfeld Strategic Advisors LLC | 827.28K | ▲ 129.69K |
| Blackrock, Inc. | 821.93K | ▼ 4.05K |
| Tig Advisors, LLC | 677.79K | ▲ 677.79K |
| Vanguard Group Inc | 623.08K | ▲ 28.17K |
| State Street Corp | 565.75K | ▼ 74.71K |
| Vanguard Capital Management LLC | 537.26K | ▲ 44.78K |
| Woodline Partners LP | 400.89K | 0 |
Held by 214 ETFs
Biggest fund positions in INBX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 14, 26 | Lappe Mark | buy | 100 |
| Oct 14, 26 | Lappe Mark | buy | 2,470 |
| Oct 14, 26 | Lappe Mark | buy | 2,470 |
| Oct 14, 26 | Lappe Mark | buy | 100 |
| Oct 14, 26 | Lappe Mark | buy | 2,451 |
| Oct 14, 26 | Lappe Mark | buy | 2,449 |
| Sep 28, 26 | Lappe Mark | buy | 3,000 |
| Sep 28, 26 | Lappe Mark | buy | 1,500 |
| Sep 25, 26 | Lappe Mark | buy | 2,176 |
| Sep 25, 26 | Lappe Mark | buy | 3,324 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our INBX coverage
Recent articles, reports, and earnings notes.
No research on INBX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INBX report →Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma
prnewswire.com · Nov 17
Inhibrx Reports Third Quarter 2026 Financial Results
prnewswire.com · Nov 13
Inhibrx Biosciences (NASDAQ:INBX) Shares Cross Below 200-Day Moving Average – Here’s What Happened
defenseworld.net · Oct 27
Inhibrx Announces Participation in Upcoming Scientific Conferences
prnewswire.com · Oct 13
Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical Contrast
defenseworld.net · Oct 5
Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
marketbeat.com · Oct 2
Inhibrx Biosciences (NASDAQ:INBX) Shares Climb 3.7% on Insider Buying Activity
defenseworld.net · Sep 30
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 3.7% Following Insider Buying Activity
defenseworld.net · Sep 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.